Skip to content
Biotechnology, Medical Health Aged Care

The Future of Skin Science: InMode and ExoCoBio introduce the most clinically validated exosome technology to New Zealand’s aesthetic market.

InMode Australia 2 mins read

This introduction brings one of the world’s most advanced exosome technologies to New Zealand, with two exclusive events set to take place in:

• Auckland – July 15, 2025 | The Boathouse, Park Hyatt Auckland, from 6:30pm

• Christchurch – July 17, 2025 | Chateau on the Park, DoubleTree by Hilton, from 6:30pm

 

These curated evenings will showcase the powerful synergy between ASCE+ Exosomes and InMode’s Morpheus8 technology, and feature:

• Live treatment demonstrations

• Keynote presentations from leading experts in regenerative science

• Clinical case studies and exclusive launch offers for attending practitioners

 

Key Speakers:

Dr Jean Paul Chung, Aesthetic Physician & Educator (Sydney), will present clinical insights and protocols using ASCE+ in skin rejuvenation.

Mr Byong Seung Cho, CEO & CTO of ExoCoBio, South Korea, will offer a rare insider’s perspective into the research and development behind ASCE+, and its role in reshaping global skin health.

 

Powered by ExoSCRT™, ExoCoBio’s proprietary purification technology, ASCE+ Exosomes are designed to optimise cell-to-cell communication, stimulate repair, and visibly revitalise the skin. Backed by science and trusted globally, ASCE+ is now set to raise the standard for non-invasive skin regeneration in the New Zealand market.

 

Adding to this innovation is the InMode Optimas Max, a powerful multi-platform workstation designed to deliver advanced skin treatments across various modalities -including radiofrequency, IPL, and laser technologies. With applicators such as Morpheus8 Burst, Lumecca Peak, and Forma, Optimas Max offers unparalleled versatility for skin resurfacing, tightening, and pigmentation correction - all in one streamlined device. It enables clinics to offer results-driven treatments with minimal downtime and maximum efficacy.

 

When paired with ASCE+ Exosomes, the Optimas Max system becomes a next-generation aesthetic powerhouse. The synergy between energy-based modalities and regenerative exosome therapy enhances treatment outcomes dramatically - accelerating recovery, improving skin texture, and promoting lasting rejuvenation. This combination delivers a compelling value proposition for clinics and practitioners committed to offering cutting-edge, science-backed solutions for their patients.

 

RSVP – https://event.inmodeau.com/asce_exosomes_nz


About us:

About InMode Australia

InMode is a market leader in energy-based medical technologies, providing cutting-edge, clinically validated solutions across Australia and New Zealand.

 

About ExoCoBio

ExoCoBio is a globally recognised innovator in exosome therapeutics and regenerative aesthetics, dedicated to delivering science-driven skincare solutions through advanced biologics.


Contact details:

Media Contact:
Patricia Amalm
Mobile: 0499 197 069
Email:
[email protected]
Website:
www.inmode.com.au

Follow Us on Instagram

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Biotechnology
  • 11/07/2025
  • 11:39
OncoSil Medical Limited (ASX:OSL)

OncoSil Medical (ASX:OSL) announces appointment of Non-Executive Director

Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) is pleased to announce the appointment of Dr Thomas Duthy as a Non-Executive Director, effective 11 July 2025. Dr Duthy brings more than 21 years of experience across financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. He was previously Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX), where he played a key role in its $1.9 billion acquisition, the largest medical device transaction in Australian history. Dr Duthy is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.